Transarterial therapies for hepatocellular carcinoma

Bibliography

• Kaczynski J, Hansson G, Wallerstedt S. Metastases in cases with hepatocellular carcinoma in relation to clinicopathologic features of the tumor an autopsy study from a low endemic area. Acta Oncol 1995;34(1):43-8
   PubMedGoogle Scholar
• Bilbao JI, de Luis E, Garcia de Jalon JA, Comparative study of four different spherical embolic particles in an animal model: a morphologic and histologic evaluation. J Vasc Interv Radiol 2008;12(11):1625-38
   Google Scholar
• Maluccio M, Covey AM, Gandhi R, Comparison of survival rates after bland arterial embolization and ablation versus surgical resection for treating solitary hepatocellular carcinoma up to 7 cm. J Vasc Interv Radiol 2005;16(7):955-61
   PubMedGoogle Scholar
• Johnson PJ, Kalayci C, Dobbs N, Pharmacokinetics and toxicity of intraarterial adriamycin for hepatocellular carcinoma: effect of coadministration of lipiodol. J Hepatol 1991;13(1):120-7
   PubMedGoogle Scholar
• Raoul JL, Heresbach D, Bretagne JF, Chemoembolization of hepatocellular carcinomas. A study of the biodistribution and pharmacokinetics of doxorubicin. Cancer 1992;70(3):585-90
   PubMedGoogle Scholar
• Chang JM, Tzeng WS, Pan HB, Transcatheter arterial embolization with or without cisplatin treatment of hepatocellular carcinoma. A randomized controlled study. Cancer 1994;74(9):2449-53
   PubMedGoogle Scholar
• Kawai S, Okamura J, Ogawa M, Prospective and randomized clinical trial for the treatment of hepatocellular carcinoma – a comparison of lipiodol-transcatheter arterial embolization with and without adriamycin (first cooperative study). The cooperative study group for liver cancer treatment of Japan. Cancer Chemother Pharmacol 1992;31(Suppl):S1-6
   PubMedGoogle Scholar
• Camma C, Schepis F, Orlando A, Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology 2002;224(1):47-54
   PubMedGoogle Scholar
• Marelli L, Stigliano R, Triantos C, Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol 2007;30(1):6-25
   PubMedGoogle Scholar
• Kudo M, Okanoue T, Japan Society of Hepatology. Management of hepatocellular carcinoma in japan: consensus-based clinical practice manual proposed by the Japan society of hepatology. Oncology. 2007;72(Suppl 1):2-15
   PubMedGoogle Scholar
• Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Available from: http://www.aasld.org/practiceguidelines/Documents/Bookmarked%20Practice%20Guidelines/HCCUpdate2010 pdf. 2010
   Google Scholar
• Llovet JM, Real MI, Montana X, Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002;359(9319):1734-9
   PubMed Web of Science ®Google Scholar
• Lo CM, Ngan H, Tso WK, Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002;35(5):1164-71
   PubMed Web of Science ®Google Scholar
• A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. Groupe d'etude et de traitement du carcinome hepatocellulaire. N Engl J Med 1995;332(19):1256-61
   PubMedGoogle Scholar
• Pelletier G, Ducreux M, Gay F, Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial. groupe CHC. J Hepatol 1998;29(1):129-34
   PubMedGoogle Scholar
• Doffoel M, Bonnetain F, Bouche O, Multicentre randomised phase III trial comparing tamoxifen alone or with transarterial lipiodol chemoembolisation for unresectable hepatocellular carcinoma in cirrhotic patients (federation francophone de cancerologie digestive 9402). Eur J Cancer 2008;44(4):528-38
   PubMedGoogle Scholar
• Pelletier G, Roche A, Ink O, A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma. J Hepatol 1990;11(2):181-4
   PubMedGoogle Scholar
• Takayasu K, Arii S, Ikai I, Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology 2006;131(2):461-9
   PubMedGoogle Scholar
• Poon RT, Ngan H, Lo CM, Transarterial chemoembolization for inoperable hepatocellular carcinoma and postresection intrahepatic recurrence. J Surg Oncol 2000;73(2):109-14
   PubMedGoogle Scholar
• O'Suilleabhain CB, Poon RT, Yong JL, Factors predictive of 5-year survival after transarterial chemoembolization for inoperable hepatocellular carcinoma. Br J Surg 2003;90(3):325-31
   PubMedGoogle Scholar
• Katyal S, Oliver JH, Peterson MS, Prognostic significance of arterial phase CT for prediction of response to transcatheter arterial chemoembolization in unresectable hepatocellular carcinoma: a retrospective analysis. AJR Am J Roentgenol 2000;175(6):1665-72
   PubMedGoogle Scholar
• Bronowicki JP, Vetter D, Dumas F, Transcatheter oily chemoembolization for hepatocellular carcinoma. A 4-year study of 127 french patients. Cancer 1994;74(1):16-24
   PubMedGoogle Scholar
• Herber SC, Otto G, Schneider J, Transarterial chemoembolization in patients not eligible for liver transplantation: single-center results. AJR Am J Roentgenol 2008;190(4):1035-42
   PubMedGoogle Scholar
• Barone M, Ettorre GC, Ladisa R, Transcatheter arterial chemoembolization (TACE) in treatment of hepatocellular carcinoma. Hepatogastroenterology 2003;50(49):183-7
   PubMedGoogle Scholar
• Llado L, Virgili J, Figueras J, A prognostic index of the survival of patients with unresectable hepatocellular carcinoma after transcatheter arterial chemoembolization. Cancer 2000;88(1):50-7
   PubMedGoogle Scholar
• Chen CH, Hu FC, Huang GT, Applicability of staging systems for patients with hepatocellular carcinoma is dependent on treatment method–analysis of 2010 taiwanese patients. Eur J Cancer 2009;45(9):1630-9
   PubMedGoogle Scholar
• Raoul JL, Sangro B, Forner A, Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization. Cancer Treat Rev 19 August 2010. [Epub ahead of print] doi: 10.1016/j.ctrv.2010.07.006
   Google Scholar
• Nouso K, Ito Y, Kuwaki K, Prognostic factors and treatment effects for hepatocellular carcinoma in child C cirrhosis. Br J Cancer 2008;98(7):1161-5
   PubMedGoogle Scholar
• Lewandowski RJ, Kulik LM, Riaz A, A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization. Am J Transplant 2009;9(8):1920-8
   PubMedGoogle Scholar
• Farinati F, De Maria N, Marafin C, Unresectable hepatocellular carcinoma in cirrhosis: Survival, prognostic factors, and unexpected side effects after transcatheter arterial chemoembolization. Dig Dis Sci 1996;41(12):2332-9
   PubMedGoogle Scholar
• Chen MS, Li JQ, Zhang YQ, High-dose iodized oil transcatheter arterial chemoembolization for patients with large hepatocellular carcinoma. World J Gastroenterol 2002;8(1):74-8
   PubMedGoogle Scholar
• Huo T, Huang YH, Wu JC, Comparison of transarterial chemoembolization and percutaneous acetic acid injection as the primary loco-regional therapy for unresectable hepatocellular carcinoma: a prospective survey. Aliment Pharmacol Ther 2004;19(12):1301-8
   PubMedGoogle Scholar
• Cho YK, Chung JW, Kim JK, Comparison of 7 staging systems for patients with hepatocellular carcinoma undergoing transarterial chemoembolization. Cancer 2008;112(2):352-61
   PubMedGoogle Scholar
• Savastano S, Miotto D, Casarrubea G, Transcatheter arterial chemoembolization for hepatocellular carcinoma in patients with child's grade A or B cirrhosis: a multivariate analysis of prognostic factors. J Clin Gastroenterol 1999;28(4):334-40
   PubMedGoogle Scholar
• Wigmore SJ, Redhead DN, Thomson BN, Postchemoembolisation syndrome–tumour necrosis or hepatocyte injury? Br J Cancer 2003;89(8):1423-7
   PubMedGoogle Scholar
• Chan AO, Yuen MF, Hui CK, A prospective study regarding the complications of transcatheter intraarterial lipiodol chemoembolization in patients with hepatocellular carcinoma. Cancer 2002;94(6):1747-52
   PubMedGoogle Scholar
• Castells A, Bruix J, Ayuso C, Transarterial embolization for hepatocellular carcinoma. antibiotic prophylaxis and clinical meaning of postembolization fever. J Hepatol 1995;22(4):410-15
   PubMedGoogle Scholar
• Chung JW, Park JH, Han JK, Hepatic tumors: predisposing factors for complications of transcatheter oily chemoembolization. Radiology 1996;198(1):33-40
   PubMedGoogle Scholar
• Pietrosi G, Miraglia R, Luca A, Arterial chemoembolization/embolization and early complications after hepatocellular carcinoma treatment: a safe standardized protocol in selected patients with child class A and B cirrhosis. J Vasc Interv Radiol 2009;20(7):896-902
   PubMedGoogle Scholar
• Kim HK, Chung YH, Song BC, Ischemic bile duct injury as a serious complication after transarterial chemoembolization in patients with hepatocellular carcinoma. J Clin Gastroenterol 2001;32(5):423-7
   PubMedGoogle Scholar
• Yu JS, Kim KW, Jeong MG, Predisposing factors of bile duct injury after transcatheter arterial chemoembolization (TACE) for hepatic malignancy. Cardiovasc Intervent Radiol 2002;25(4):270-4
   PubMedGoogle Scholar
• Chen JH, Ho YJ, Shen WC. Asymptomatic arterio-biliary fistula after transarterial chemoembolization of metastatic liver tumors. Hepatogastroenterology 2001;48(39):842-3
   PubMedGoogle Scholar
• Leung TK, Lee CM, Chen HC. Anatomic and technical skill factor of gastroduodenal complication in post-transarterial embolization for hepatocellular carcinoma: a retrospective study of 280 cases. World J Gastroenterol 2005;11(10):1554-7
   PubMedGoogle Scholar
• Shi M, Chen JA, Lin XJ, Transarterial chemoembolization as initial treatment for unresectable hepatocellular carcinoma in southern china. World J Gastroenterol 2010;16(2):264-9
   PubMedGoogle Scholar
• Luo J, Guo RP, Lai EC, Transarterial chemoembolization for unresectable hepatocellular carcinoma with portal vein tumor thrombosis: a prospective comparative study. Ann Surg Oncol 2011;18:413-20
   Google Scholar
• Kim KM, Kim JH, Park IS, Reappraisal of repeated transarterial chemoembolization in the treatment of hepatocellular carcinoma with portal vein invasion. J Gastroenterol Hepatol 2009;24(5):806-14
   PubMedGoogle Scholar
• Hong K, Georgiades CS, Geschwind JF. Technology insight: image-guided therapies for hepatocellular carcinoma–intra-arterial and ablative techniques. Nat Clin Pract Oncol 2006;3(6):315-24
   PubMedGoogle Scholar
• Jordan O, Denys A, De Baere T, Comparative study of chemoembolization loadable beads: in vitro drug release and physical properties of DC bead and hepasphere loaded with doxorubicin and irinotecan. J Vasc Interv Radiol 2010;21(7):1084-90
   PubMedGoogle Scholar
• Poon RT, Tso WK, Pang RW, A phase I/II trial of chemoembolization for hepatocellular carcinoma using a novel intra-arterial drug-eluting bead. Clin Gastroenterol Hepatol 2007;5(9):1100-8
   PubMedGoogle Scholar
• Varela M, Real MI, Burrel M, Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol 2007;46(3):474-81
   PubMed Web of Science ®Google Scholar
• Malagari K, Pomoni M, Kelekis A, Prospective randomized comparison of chemoembolization with doxorubicin-eluting beads and bland embolization with BeadBlock for hepatocellular carcinoma. Cardiovasc Intervent Radiol 2010;33(3):541-51
   PubMedGoogle Scholar
• Lammer J, Malagari K, Vogl T, Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol 2010;33(1):41-52
   PubMed Web of Science ®Google Scholar
• Grosso M, Vignali C, Quaretti P, Transarterial chemoembolization for hepatocellular carcinoma with drug-eluting microspheres: preliminary results from an italian multicentre study. Cardiovasc Intervent Radiol 2008;31(6):1141-9
   PubMedGoogle Scholar
• Kim KW, Bae SK, Lee OH, Insulin-like growth factor II induced by hypoxia may contribute to angiogenesis of human hepatocellular carcinoma. Cancer Res 1998;58(2):348-51
   PubMedGoogle Scholar
• von Marschall Z, Cramer T, Hocker M, Dual mechanism of vascular endothelial growth factor upregulation by hypoxia in human hepatocellular carcinoma. Gut 2001;48(1):87-96
   PubMedGoogle Scholar
• Xiong ZP, Yang SR, Liang ZY, Association between vascular endothelial growth factor and metastasis after transcatheter arterial chemoembolization in patients with hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 2004;3(3):386-90
   PubMedGoogle Scholar
• Strebel BM, Dufour JF. Combined approach to hepatocellular carcinoma: a new treatment concept for nonresectable disease. Expert Rev Anticancer Ther 2008;8(11):1743-9
   PubMed Web of Science ®Google Scholar
• Llovet JM, Ricci S, Mazzaferro V, Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359(4):378-90
   PubMed Web of Science ®Google Scholar
• Available from: http://www.clinicaltrials.gov/ct2/results?term=hepatocellular+carcinoma+TACE+sorafenib
   Google Scholar
• Gish RG, Gordon SC, Nelson D, A randomized controlled trial of thymalfasin plus transarterial chemoembolization for unresectable hepatocellular carcinoma. Hepatol Int 2009;3(3):480-9
   Google Scholar
• Li M, Lu C, Cheng J, Combination therapy with transarterial chemoembolization and interferon-alpha compared with transarterial chemoembolization alone for hepatitis B virus related unresectable hepatocellular carcinoma. J Gastroenterol Hepatol 2009;24(8):1437-44
   PubMedGoogle Scholar
• Lawrence TS, Robertson JM, Anscher MS, Hepatic toxicity resulting from cancer treatment. Int J Radiat Oncol Biol Phys 1995;31(5):1237-48
   PubMedGoogle Scholar
• Yoo HS, Lee JT, Kim KW, Nodular hepatocellular carcinoma. treatment with subsegmental intraarterial injection of iodine 131-labeled iodized oil. Cancer 1991;68(9):1878-84
   PubMedGoogle Scholar
• Raoul JI, Bretagne JF, Caucanas JP, Internal radiation therapy for hepatocellular carcinoma. results of a french multicenter phase II trial of transarterial injection of iodine 131-labeled lipiodol. Cancer 1992;69(2):346-52
   PubMedGoogle Scholar
• Leung WT, Lau WY, Ho S, Selective internal radiation therapy with intra-arterial iodine-131-lipiodol in inoperable hepatocellular carcinoma. J Nucl Med 1994;35(8):1313-18
   PubMedGoogle Scholar
• Raoul JL, Guyader D, Bretagne JF, Randomized controlled trial for hepatocellular carcinoma with portal vein thrombosis: intra-arterial iodine-131-iodized oil versus medical support. J Nucl Med 1994;35(11):1782-7
   PubMedGoogle Scholar
• Raoul JL, Guyader D, Bretagne JF, Prospective randomized trial of chemoembolization versus intra-arterial injection of 131I-labeled-iodized oil in the treatment of hepatocellular carcinoma. Hepatology 1997;26(5):1156-61
   PubMedGoogle Scholar
• Marelli L, Shusang V, Buscombe JR, Transarterial injection of (131)I-lipiodol, compared with chemoembolization, in the treatment of unresectable hepatocellular cancer. J Nucl Med 2009;50(6):871-7
   PubMedGoogle Scholar
• Kennedy A, Nag S, Salem R, Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the radioembolization brachytherapy oncology consortium. Int J Radiat Oncol Biol Phys 2007;68(1):13-23
   PubMedGoogle Scholar
• Coldwell D, Sangro B, Wasan H, General selection criteria of patients for radioembolization of liver tumors: an international working group report. Am J Clin Oncol 1 Oct 2010. [Epub ahead of print] doi: 10.1097/COC.0b013e3181ec61bb
   Google Scholar
• Young JY, Rhee TK, Atassi B, Radiation dose limits and liver toxicities resulting from multiple yttrium-90 radioembolization treatments for hepatocellular carcinoma. J Vasc Interv Radiol 2007;18(11):1375-82
   PubMedGoogle Scholar
• Lau WY, Leung WT, Ho S, Treatment of inoperable hepatocellular carcinoma with intrahepatic arterial yttrium-90 microspheres: a phase I and II study. Br J Cancer 1994;70(5):994-9
   PubMedGoogle Scholar
• Lau WY, Ho S, Leung TW, Selective internal radiation therapy for nonresectable hepatocellular carcinoma with intraarterial infusion of 90yttrium microspheres. Int J Radiat Oncol Biol Phys 1998;40(3):583-92
   PubMedGoogle Scholar
• Dancey JE, Shepherd FA, Paul K, Treatment of nonresectable hepatocellular carcinoma with intrahepatic 90Y-microspheres. J Nucl Med 2000;41(10):1673-81
   PubMedGoogle Scholar
• Carr BI. Hepatic arterial 90Yttrium glass microspheres (therasphere) for unresectable hepatocellular carcinoma: interim safety and survival data on 65 patients. Liver Transpl 2004;10(2):S107-10
   PubMedGoogle Scholar
• Geschwind JF, Salem R, Carr BI, Yttrium-90 microspheres for the treatment of hepatocellular carcinoma. Gastroenterology 2004;127(5):S194-205
   Google Scholar
• Salem R, Lewandowski RJ, Atassi B, Treatment of unresectable hepatocellular carcinoma with use of 90Y microspheres (TheraSphere): safety, tumor response, and survival. J Vasc Interv Radiol 2005;16(12):1627-39
   PubMedGoogle Scholar
• Salem R, Lewandowski RJ, Mulcahy MF, Radioembolization for hepatocellular carcinoma using yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology 2010;138(1):52-64
   PubMedGoogle Scholar
• Sangro B, Bilbao JI, Boan J, Radioembolization using 90Y-resin microspheres for patients with advanced hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2006;66(3):792-800
   PubMedGoogle Scholar
• Kulik LM, Carr BI, Mulcahy MF, Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology 2008;47(1):71-81
   PubMedGoogle Scholar
• Gaba RC, Lewandowski RJ, Kulik LM, Radiation lobectomy: preliminary findings of hepatic volumetric response to lobar yttrium-90 radioembolization. Ann Surg Oncol 2009;16(6):1587-96
   PubMedGoogle Scholar
• Inarrairaegui M, Martinez-Cuesta A, Rodriguez M, Analysis of prognostic factors after yttrium-90 radioembolization of advanced hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2010;77(5):1441-8
   PubMedGoogle Scholar
• Goin JE, Salem R, Carr BI, Treatment of unresectable hepatocellular carcinoma with intrahepatic yttrium 90 microspheres: factors associated with liver toxicities. J Vasc Interv Radiol 2005;16(2):205-13
   PubMedGoogle Scholar
• Goin JE, Salem R, Carr BI, Treatment of unresectable hepatocellular carcinoma with intrahepatic yttrium 90 microspheres: a risk-stratification analysis. J Vasc Interv Radiol 2005;16(2):195-203
   PubMedGoogle Scholar
• D'Avola D, Lnarrairaegui M, Bilbao JI, A retrospective comparative analysis of the effect of Y90-radioembolization on the survival of patients with unresectable hepatocellular carcinoma. Hepatogastroenterology 2009;56(96):1683-8
   PubMedGoogle Scholar
• Kulik LM, Atassi B, van Holsbeeck L, Yttrium-90 microspheres (TheraSphere) treatment of unresectable hepatocellular carcinoma: downstaging to resection, RFA and bridge to transplantation. J Surg Oncol 2006;94(7):572-86
   PubMedGoogle Scholar
• Woodall CE, Scoggins CR, Ellis SF, Is selective internal radioembolization safe and effective for patients with inoperable hepatocellular carcinoma and venous thrombosis? J Am Coll Surg 2009;208(3):375-82
   PubMedGoogle Scholar
• Inarrairaegui M, Thurston KG, Bilbao JI, Radioembolization with use of yttrium-90 resin microspheres in patients with hepatocellular carcinoma and portal vein thrombosis. J Vasc Interv Radiol 2010;21(8):1205-12
   PubMedGoogle Scholar
• Riaz A, Kulik L, Lewandowski RJ, Radiologic-pathologic correlation of hepatocellular carcinoma treated with internal radiation using yttrium-90 microspheres. Hepatology 2009;49(4):1185-93
   PubMedGoogle Scholar
• Sato K, Lewandowski RJ, Bui JT, Treatment of unresectable primary and metastatic liver cancer with yttrium-90 microspheres (TheraSphere): assessment of hepatic arterial embolization. Cardiovasc Intervent Radiol 2006;29(4):522-9
   PubMedGoogle Scholar
• Bilbao J, de Martino A, de Luis E, Biocompatibility, inflammatory response, and recannalization characteristics of nonradioactive resin microspheres: histological findings. Cardiovasc Intervent Radiol 2009;32:727-36
   Google Scholar
• Carretero C, Munoz-Navas M, Betes M, Gastroduodenal injury after radioembolization of hepatic tumors. Am J Gastroenterol 2007;102(6):1216-20
   PubMedGoogle Scholar
• Leung TW, Lau WY, Ho SK, Radiation pneumonitis after selective internal radiation treatment with intraarterial 90yttrium-microspheres for inoperable hepatic tumors. Int J Radiat Oncol Biol Phys 1995;33(4):919-24
   PubMedGoogle Scholar
• Sangro B, Gil-Alzugaray B, Rodriguez J, Liver disease induced by radioembolization of liver tumors: description and possible risk factors. Cancer 2008;112(7):1538-46
   PubMedGoogle Scholar
• Kooby DA, Egnatashvili V, Srinivasan S, Comparison of yttrium-90 radioembolization and transcatheter arterial chemoembolization for the treatment of unresectable hepatocellular carcinoma. J Vasc Interv Radiol 2010;21(2):224-30
   PubMedGoogle Scholar
• Carr BI, Kondragunta V, Buch SC, Branch RA. Therapeutic equivalence in survival for hepatic arterial chemoembolization and yttrium 90 microsphere treatments in unresectable hepatocellular carcinoma: a two-cohort study. Cancer 2010;116(5):1305-14
   PubMedGoogle Scholar
• Borbath I, Lhommel R, Bittich L, 131I-Labelled-iodized oil for palliative treatment of hepatocellular carcinoma. Eur J Gastroenterol Hepatol 2005;17(9):905-10
   PubMedGoogle Scholar